JAN 13, 2022
Cataract/Anterior Segment, Comprehensive Ophthalmology, Refractive Mgmt/Intervention
0.5 General AMA PRA Category 1 Credits™
Drs. Meron Haile and Daniel Choi rejoin the show to break down conventional interventions and newer pharmacologic advances in presbyopia management, including the recently FDA-approved pilocarpine eye drop (Vuity; Allergan).
Want More Resources on Presbyopia?
Get text alerts from the Academy for more resources on presbyopia management and help us better serve your educational needs.
Sign up for text alerts or Text PODCAST to 415.236.9439
Release: January 13, 2022; expires January 13, 2025
Participants: Drs. Choi, Haile, and Sridhar report no relevant financial disclosures.
Review Panel: The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MPH; Mazeyar Saboori, MD; Annie Moreau, MD; and Allison Umfress, MD.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care in refractive cataract surgery or the outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.